An2 Therapeutics Stock Today
| ANTX Stock | USD 1.46 0.05 3.55% |
PerformanceModest
| Odds Of DistressAverage
|
AN2 Therapeutics is trading at 1.46 as of the 19th of March 2025; that is 3.55 percent increase since the beginning of the trading day. The stock's open price was 1.41. AN2 Therapeutics has over 55 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of March 2022 | Category Healthcare | Classification Health Care |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California. An2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 29.88 M outstanding shares of which 78.58 K shares are presently shorted by private and institutional investors with about 0.75 trading days to cover. More on AN2 Therapeutics
Moving against AN2 Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
AN2 Stock Highlights
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
AN2 Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AN2 Therapeutics' financial leverage. It provides some insight into what part of AN2 Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
AN2 Therapeutics (ANTX) is traded on NASDAQ Exchange in USA. It is located in 1800 El Camino Real, Menlo Park, CA, United States, 94027 and employs 41 people. AN2 Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.13 M. AN2 Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 29.88 M outstanding shares of which 78.58 K shares are presently shorted by private and institutional investors with about 0.75 trading days to cover.
AN2 Therapeutics currently holds about 113.39 M in cash with (53.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check AN2 Therapeutics Probability Of Bankruptcy
Ownership AllocationAN2 Therapeutics secures a total of 29.88 Million outstanding shares. AN2 Therapeutics shows tangible amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check AN2 Ownership Details
AN2 Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-12-31 | 385.5 K | |
| Aldebaran Capital Llc | 2024-12-31 | 343.7 K | |
| Adage Capital Partners Gp Llc | 2024-12-31 | 312.6 K | |
| Blackrock Inc | 2024-12-31 | 301.4 K | |
| Geode Capital Management, Llc | 2024-12-31 | 227.8 K | |
| Millennium Management Llc | 2024-12-31 | 209.4 K | |
| Stonepine Capital Management Llc | 2024-12-31 | 196.7 K | |
| Ubs Group Ag | 2024-12-31 | 170.3 K | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 162.2 K | |
| Bml Capital Management Llc | 2024-12-31 | 5.7 M | |
| Almitas Capital Llc | 2024-12-31 | 1.3 M |
AN2 Therapeutics Historical Income Statement
AN2 Stock Against Markets
AN2 Therapeutics Corporate Management
| MBA BS | Chief Officer | Profile | |
| Vince Hernandez | Senior Chemistry | Profile | |
| Eric Easom | CEO, Cofounder | Profile | |
| Michael Alley | CoFounder Biology | Profile | |
| Stephen Prior | Chief Officer | Profile | |
| Paul MD | Chief Officer | Profile |
Already Invested in AN2 Therapeutics?
The danger of trading AN2 Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AN2 Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AN2 Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AN2 Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.